Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,435,552
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.73
  • Price/Sales 4.57
  • Price/Cash Flow 13.62
  • Price/Book 5.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.03
  • Number of Estimates 8
  • High Estimate 2.09
  • Low Estimate 2.00
  • Prior Year 1.90
  • Growth Rate Est. (year over year) +6.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.16 +4.30%
on 07/16/18
133.00 -2.63%
on 08/02/18
+3.57 (+2.83%)
since 07/13/18
3-Month
118.62 +9.17%
on 05/29/18
133.00 -2.63%
on 08/02/18
+3.44 (+2.73%)
since 05/14/18
52-Week
118.62 +9.17%
on 05/29/18
148.32 -12.69%
on 01/17/18
-3.98 (-2.98%)
since 08/14/17

Most Recent Stories

More News
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

The Janssen Pharmaceutical Companies of Johnson & Johnson today confirmed positive topline results from the global, Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study of the first...

JNJ : 129.50 (-0.55%)
Johnson&Johnson (JNJ) Crosses Pivot Point Support at $129.75

Shares of Johnson&Johnson (NYSE:JNJ) have bearishly opened below the pivot of $130.32 today and have reached the first support level of $129.75. Investors may be interested in a cross of the next downside...

JNJ : 129.50 (-0.55%)
FDA Approvals for Cardiac Electrophysiology Products Bright Spot in Healthcare Industry

MarketNewsUpdates.com News Commentary

ECOR : 13.62 (-2.37%)
ABT : 63.63 (+0.32%)
BSX : 33.70 (+1.20%)
JNJ : 129.50 (-0.55%)
BSGM : 2.6200 (-12.67%)
Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

JNJ : 129.50 (-0.55%)
SHPG : 169.13 (-0.35%)
GILD : 77.31 (+0.18%)
PFE : 40.71 (-0.25%)
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations

Johnson & Johnson (NYSE: JNJ) announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018. Mr. DelOrefice will report to...

JNJ : 129.50 (-0.55%)
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

VVUS : 0.65 (-2.99%)
JNJ : 129.50 (-0.55%)
GILD : 77.31 (+0.18%)
SGEN : 74.63 (+1.12%)
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type...

JNJ : 129.50 (-0.55%)
Global Adhesion Barriers Market 2018-2022 featuring Key Players Baxter International, BD, FzioMed, Johnson & Johnson, Medtronic, and Sanofi - ResearchAndMarkets.com

The "Global Adhesion Barriers Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

JNJ : 129.50 (-0.55%)
BAX : 70.71 (unch)
MDT : 91.05 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 130.89
1st Resistance Point 130.20
Last Price 129.50
1st Support Level 129.08
2nd Support Level 128.65

See More

52-Week High 148.32
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
Last Price 129.50
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar